MENU
+Compare
AKBA
Stock ticker: NASDAQ
AS OF
Jun 5, 04:59 PM (EDT)
Price
$3.70
Change
+$0.06 (+1.65%)
Capitalization
971.75M

AKBA Akebia Therapeutics Forecast, Technical & Fundamental Analysis

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company... Show more

Industry: #Biotechnology
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AKBA with price predictions
Jun 04, 2025

Aroon Indicator for AKBA shows an upward move is likely

AKBA's Aroon Indicator triggered a bullish signal on June 04, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 178 similar instances where the Aroon Indicator showed a similar pattern. In of the 178 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AKBA advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AKBA broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKBA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (39.526) is normal, around the industry mean (16.306). P/E Ratio (0.000) is within average values for comparable stocks, (59.921). AKBA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (4.405) is also within normal values, averaging (265.014).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AKBA is expected to report earnings to fall 166.67% to -1 cents per share on July 31

Akebia Therapeutics AKBA Stock Earnings Reports
Q2'25
Est.
$-0.02
Q1'25
Beat
by $0.08
Q4'24
Missed
by $0.03
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.03
The last earnings report on May 08 showed earnings per share of 2 cents, beating the estimate of -5 cents. With 5.72M shares outstanding, the current market capitalization sits at 971.75M.
A.I. Advisor
published General Information

General Information

a developer of drugs for the treatment of anemia and vascular diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
245 First Street
Phone
+1 617 871-2098
Employees
167
Web
https://www.akebia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICEVX44.090.38
+0.87%
NYLI Epoch International Choice Class A
NBMRX25.23N/A
N/A
Neuberger Berman M/C Intrinsic Val R6
SCMIX144.27N/A
N/A
Columbia Seligman Tech & Info Inst2
SGMIX10.72N/A
N/A
SEI Global Managed Volatility I (SIMT)
JIJRX14.70N/A
N/A
JHancock International Dynamic Gr R6

AKBA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+6.43%
XERS - AKBA
42%
Loosely correlated
-4.73%
ATOS - AKBA
40%
Loosely correlated
+0.57%
ADAP - AKBA
40%
Loosely correlated
-1.25%
ABOS - AKBA
39%
Loosely correlated
+2.88%
FHTX - AKBA
39%
Loosely correlated
-3.67%
More

Groups containing AKBA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+6.43%
Pharmaceuticals
category (298 stocks)
17%
Poorly correlated
-0.33%